Radiopharm secures $8M advance against FY26 R&D tax incentive
Radiopharm Theranostics (ASX: RAD; Nasdaq: RADX) has received $8,000,000 from Rockford Capital under a funding facility secured against its anticipated FY26 Research and Development Tax Incentive (RDTI). The R&D tax incentive advance was announced on 26 October 2026.
The funds will support the clinical trial pipeline and otherwise be used for general working capital. The funding agreement gives the company early access to a portion of its anticipated FY26 RDTI, which may help keep its trials moving.
The announcement was authorised on behalf of the board by Executive Chairman Paul Hopper.
When big ASX news breaks, our subscribers know first
How the Rockford Capital facility works
The facility is structured as an advance against a government incentive. The key terms are:
- Amount received: $8,000,000 from Rockford Capital
- Security: the anticipated FY26 RDTI to be received from the Australian Taxation Office
- Interest: charged at a commercial rate
- Repayment: timed to follow the anticipated receipt of the FY26 RDTI, and due by 26 October 2027
- Early repayment: the facility can be repaid at any time without penalty prior to the due date
The no-penalty early repayment option gives the company flexibility in managing its balance sheet, as the facility can be repaid before the due date if it chooses.
Understanding the R&D tax incentive
The Australian Government RDTI program provides companies engaging in eligible activities with a refundable tax offset of up to 43.5%.
A refundable offset means eligible companies can receive cash back rather than only reducing a tax bill. For a clinical-stage biotech that is not yet generating profits, that distinction matters.
An advance against the RDTI brings forward a portion of that expected refund. Investors may view this as a way to access funding earlier, secured against the incentive rather than through a new share issue.
Radiopharm has already seen the incentive convert to cash once, with a FY2025 R&D tax refund of roughly $5.9 million received in July 2026 and directed at the same clinical pipeline.
| Term | Fact | Impact |
|---|---|---|
| Amount | **$8,000,000** | Supports the clinical trial pipeline and general working capital |
| Security | Anticipated FY26 RDTI | Secured against the incentive |
| Early repayment | No penalty prior to due date | Repayment flexibility |
What happens next for Radiopharm
Two items follow from the announcement:
- Repayment of the Rockford Capital facility: timed to follow the anticipated receipt of the FY26 RDTI from the Australian Taxation Office, and due by 26 October 2027. The facility can be repaid earlier without penalty.
- Receipt of the FY26 RDTI: anticipated from the Australian Taxation Office.
Pipeline the funds support
Radiopharm describes itself as a clinical stage radiotherapeutics company. Its clinical program includes one Phase 2 and five Phase 1 trials in solid tumor cancers including lung, breast, prostate and brain.
The company’s platform technologies span peptides, small molecules and monoclonal antibodies for use in cancer. Radiopharm is listed on ASX (RAD) and Nasdaq (RADX).
The RAD202 HEAT trial, targeting HER2-positive solid tumors, has cleared a third consecutive dose escalation to 180mCi in Cohort 4 after a favourable safety review.
Get Biotech News Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX alerts within minutes of release, complete with in-depth analysis and the full announcement. Click the “Free Alerts” button at Big News Blast to get healthcare and biotech news the moment it breaks and stay ahead of the crowd.